Recon: Emergent’s OTC opioid overdose drug Narcan to hit the shelves next week; J&J slashes price of its oral TB pill in developing countries

• Opioid overdose antidote Narcan will be widely available over the counter next week (NBC News)
• A big insurer decides to cover naloxone for overdose; will others follow? (STAT)
• US senators push drugmakers for details on low-cost insulin programs (Reuters)
• Insulin Makers Facing Price Talks Appear Poised to File Lawsuits (Bloomberg Law)
• Republican governors call on Congress to take more action on US drug shortages (Fierce Pharma)
• AmerisourceBergen is no more as it drops its 2-decade-old merger name to become Cencora (Fierce Pharma)
• US FDA warns 3 baby formula makers to correct manufacturing process controls (Reuters) (FDA)

• Europe to face shortage of Lilly's diabetes drug through September (Reuters)
• J&J cuts the price of its lifesaving TB pill by more than half for many low- and middle-income countries (STAT)
• Pharma Firm, Labs Share Tech For Covid Research Equity: WHO (Agence-France Press)
• Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 (EMA)
• China's CanSino seeks more vaccine contracts after AstraZenca deal (Reuters)
• Otsuka to acquire Mindset Pharma (Endpoints)
• UK regulators name 3 approved bodies to ease device certification bottleneck (MedTech Dive)
• Pharma keeps pandemic halo in eyes of UK public, but pricing is a problem (Fierce Pharma)
• India invites bids for privatisation of Indian Medicines Pharmaceutical (Reuters)

• Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
• Sage remains tight-lipped on postpartum launch plans in wake of restructuring (Endpoints)
• Pot firms surge as US move to ease curbs sparks hopes of legalization (Reuters)
• One dose of psilocybin may have lasting effects on major depression, study finds (STAT)
• Drug firms test medicines to halt Alzheimer’s before symptoms appear (STAT)
• As Revlimid sales fall, Bristol Myers turns to its next multiple myeloma pill that's a molecular glue (Endpoints)
• Zevra beefs up rare disease portfolio via $91M acquisition of Acer Therapeutics (Endpoints)
• Alkermes, Teva settle patent suit around opioid-blocker Vivitrol, paving way for generics after three-year fight (Endpoints)
• Exclusive: Stem cell scientist and bit.bio founder launches new startup with goal of extending healthspan by 20 years (Endpoints)
• Sanofi taps serial biotech investor, entrepreneur as R&D chief — while promoting business operations, digital leaders (Endpoints)
• Incyte nets soccer legend Mia Hamm for a personal touch on GvHD awareness (Fierce Pharma)

• Blood test for Parkinson's disease promising in early study (Reuters)
• Hamilton Medical’s urgent ventilator notice deemed Class I recall by FDA (MedTech Dive)
• No longer brushed off: A Minnesota clinic tries to rewrite medicine’s approach to miscarriage (STAT)
• Unicorn down: Following layoffs, Biofourmis CEO quietly departs (STAT)
• Abbott study shows benefits of OCT imaging in stent placement (MedTech Dive)
• Why medtech firms are putting diabetes tech in consumer devices (MedTech Dive)
• Trade groups urge CMS to expand, quickly finalize breakthrough device pathway (MedTech Dive)

• Drugmakers could find sympathetic US Supreme Court in drug pricing lawsuits (Reuters)
• Medicaid rebukes states for mistakenly disenrolling children (STAT)